Discovering, validating, and approving a drug historically costs upwards of $2.6 billion and can take over a decade. Vast inefficiencies exist across each stage:

Screening Bottlenecks

• Conventional wet-lab screening requires years for each therapeutic candidate, with early-stage attrition rates over 90%.
• AI-enabled virtual screening tools now scan millions of compounds per day, boosting hit rates 500x and shrinking candidate selection to weeks.

Clinical Trial Delays

• About 30% of trial delays arise from slow and inefficient patient recruitment and site selection.
• AI-driven trial design and adaptive enrollment can speed timelines by up to 80%.

Regulatory Compliance Challenges

• Manual documentation and compliance management remain major stumbling blocks, with up to 10% of trial effort spent on regulatory paperwork.
• AI-based workflow automation ensures timely, accurate regulatory filings, proactively detecting and addressing compliance risks.

Safety and Adverse Event Monitoring

• Human-led monitoring can miss emerging safety signals and adverse event clusters until late in a trial.
• AI delivers real-time alerts and trend analyses, safeguarding patient safety around the clock.